Medicare’s prescription-drug coverage will ask beneficiaries to pay more out of pocket before it kicks in next year. The standard Part D deductible rises to $700 in 2027, up from $615 in 2026, a figure the Centers for Medicare & Medicaid Services finalized in its rate announcement for the coming year. The deductible is the sum a beneficiary covers first, before a drug plan begins paying its share, and the $85 increase resets the starting line for tens of millions of enrollees who fill prescriptions under Part D.
What the standard deductible covers before a plan pays
The deductible marks the first phase of Part D coverage: until a beneficiary has spent the full amount on covered drugs, the plan pays nothing and the enrollee bears the cost at the pharmacy counter. Only after that threshold is met does the plan move into cost-sharing, where it picks up most of the tab. Medicare details this sequence in its explanation of drug-coverage costs, and the deductible sits at the front of it.
The $700 figure is a standard, or maximum, deductible set in law, not a flat charge every plan imposes. Individual Part D plans may set a lower deductible, or none at all, and instead recover the difference through higher premiums or copayments. The consequence is that two enrollees can hit their first covered drug of the year and pay wildly different amounts depending on how their specific plan is designed around that ceiling.
Free retirement updates: Social Security and Medicare change every year, and nobody sends a memo. The free Retirement Shield newsletter breaks down what changed and what to do. Get it free in your inbox.
How CMS set the $700 figure for 2027
The new deductible was not a projection or a proposal; the Centers for Medicare & Medicaid Services locked it in when it released its 2027 rate announcement on April 6, 2026, according to a summary of the finalized 2027 figures. That makes the $700 amount a settled number for plan year 2027, not a target that could still shift before enrollment.
The standard deductible is indexed to the growth in per-capita Part D costs, which is why it drifts upward most years rather than holding flat. The move from $615 to $700 continues a steady climb that has pushed the threshold higher across the redesigned benefit, and it reflects rising drug spending across the program rather than a policy choice to shift more cost onto enrollees in any single year.
Because the figure is confirmed well ahead of the fall enrollment period, beneficiaries comparing plans for 2027 can treat it as fixed. What still varies is how each plan handles the deductible — whether it charges the full $700, a reduced amount, or waives it — so the number matters most as a reference point against which competing plans can be measured.
Where the deductible fits in the redesigned Part D benefit
The deductible is only the entry point of a Part D structure that Congress reshaped in recent years. After a beneficiary clears the deductible, the plan and enrollee share costs until total out-of-pocket spending reaches an annual cap, at which point covered drugs cost nothing for the rest of the year. That hard ceiling on spending is the headline feature of the current design, and the deductible determines how quickly a beneficiary begins the climb toward it.
The redesign also eliminated the old coverage gap, the so-called donut hole that once caused drug costs to spike partway through the year. With that phase gone and a firm out-of-pocket maximum in place, the deductible and the cap now bracket the beneficiary’s exposure: the deductible sets the floor of what everyone pays first, and the cap sets the ceiling of what anyone pays in total.
The cap that now backstops the benefit is a concrete dollar figure. Beginning in 2025, Part D placed a hard limit on what any enrollee pays out of pocket for covered drugs in a year — $2,000 — with the ceiling indexed to rise in the years that follow. Once a beneficiary’s spending reaches that limit, covered prescriptions cost nothing for the rest of the year, a protection that did not exist under the program’s earlier design. Alongside it sits a newer option, the Medicare Prescription Payment Plan, which lets enrollees spread their out-of-pocket drug costs into level monthly installments across the calendar year rather than paying a large sum at the pharmacy at once. It does not lower the total owed or touch the $700 deductible met first, but it changes the rhythm of when a beneficiary pays.
For a beneficiary who takes only occasional, inexpensive medications, a $700 deductible may be the most they encounter all year, since they never spend enough to reach the plan’s cost-sharing phase. Medicare’s overview of program costs underscores how much of a light user’s drug spending can consist of the deductible alone. For someone on high-cost specialty drugs, by contrast, the deductible is a brief first step before the annual cap does the heavier lifting.
The rising deductible is therefore best understood as one dial among several in a benefit built to trade a higher entry cost for a firm limit on the worst-case year. The $700 threshold will hit light and heavy users differently, but it lands on every enrollee first, before any plan pays a dollar. Reading it alongside the annual cap, rather than in isolation, is what tells a beneficiary where the real exposure sits for 2027.
This article was produced with AI assistance and reviewed by The Money Overview editorial team.
More Financial Reading
